Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Speaker
Nirankar Singh Neki (Faculty)
Government Medical college, India
Biography

Dr. Nirankar Singh Neki, MBBS, MD(Internal Medicine) is working as Professor and Head of Medicine unit 2 at Govt. Medical College Amritsar, India. He has teaching experience of 30 years as an undergraduate teacher and 28 years as a postgraduate teacher. He has an entry in the Limca Book of Records of 2015 for being the recipient of four Fellowships of the Royal College of Physicians (Edinburgh, Glasgow, Ireland, and London). In total, he has 38 fellowship awards with different institutes. He is the recipient of FACC (USA), FAHA (USA), FESC, FACP(USA), and holds name in cardiology .Dr. Neki holds 13 different Oration Awards and has been a named author in 365 scientific publications, including book chapters. He is also Editor in Chief, Senior Editor, Editor, Section Editor, and Associate Editor of more than 13 national and international medical journals. Dr. Neki has been a Visiting Professor at James Cook University Hospital in Durham, UK and at the University of Manitoba's Institute of Cardiovascular Sciences at St. Boniface Hospital &Research Centre, Winnipeg, Canada.

Abstract

Antiplatelets are mainly used in the prevention and management of atherothrombotic complications. Current ACC/AHA/ESC guidelines suggest dual antiplatelet therapy (combining aspirin & clopidogrel) for patients having acute coronary syndromes or undergoing PCI. But in spite of administration of dual antiplatelet therapy, some patients develop recurrent cardiovascular ischemic events especially stent thrombosis which is a serious clinical problem. Clopidogrel is an effective inhibitor of platelet activation and aggregation due to selective and irreversible blockade of the P2Y2 receptors. The mechanism of clopidogrel resistance remains incompletely defined but there are certain clinical, cellular and genetic factors including polymorphisms responsible for therapeutic failure. The prevalence of clopidogrel nonresponse varies from 4% to 30% 24 hours after administration. Currently there is no standardized or widely accepted definition of clopidogrel resistance. This presentation is focussed on the methods used to identify patients with clopidogrel resistance, the underlying mechanisms, metabolism, clinical significance and current therapeutic strategies to overcome clopidogrel resistance.

Allied Academies Global Conference Directory

Mail us at

Program enquiry
heartdiseases@alliedconferences.org
Sponsors / Exhibiting / Advertising
heartdiseases@alliedconferences.com
General Queries
heartdiseases@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

Insurance

Registration fees do not include insurance of any kind.

Transportation

Please note that any (or) all transportation and parking is the responsibility of the registrant.

Press/Media

Press permission must be obtained from Allied Academies Conferences Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party non-profit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact heartdiseases@alliedconferences.org to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrants account.

This cancellation policy was last updated on November 25, 2016.

Authorization Policy


Copyright © 2018-2019 Allied Academies, All Rights Reserved.